‘Penicillin’ breakthrough in cancer treatment?
September 15th, 2010 - 5:59 pm ICT by IANSLondon, Sep 15 (IANS) Scientists have hailed as yet another “penicillin moment” the successful clinical trial of a new drug that could halt or reverse the growth of cancer in the human body.
The trials of a drug developed by the US scientists have raised hopes that drug manufacturers will be able to tailor drugs to individual cancers that will halt them in their tracks and even reverse the growth of existing tumours, The Daily Telegraph reported Wednesday.
As part of the latest research, scientists in California developed a drug to block the effects of a specific gene mutation, B-RAF, linked to malignant melanoma - one of the deadliest cancers.
The experts found that tumours shrank by at least 30 percent in 24 out of 32 patients with B-RAF mutations, and disappeared entirely in two other patients.
However, the drug cannot be declared a success. It comes with side-effects, can only treat the specific B-RAF mutation and there are no indications of its long-term usefulness.
The chemical process behind the drug, detailed in the journal Nature, demonstrates the potential for speedy development of similar treatments targeting the particular genetic mutations that lie behind different types of tumour.
Professor Mark Stratton, Director of the Wellcome Trust Sanger Institute in Cambridge, which first linked B-RAF to malignant melanoma, said: “We’ve entered an end game in which we are going to complete our understanding of what causes cancer.”
Yardena Samuels, a cancer geneticist at the National Human Genome Research Institute in Bethesda, Maryland, told Nature News: “It’s a very important development, not just for melanoma, but for the entire cancer field.”
The company behind the research is now working on a test that can diagnose which malignant melanoma patients have the B-RAF mutation and would therefore benefit from the drug.
Sir Mark Walport, director of the Wellcome Trust, agreed with suggestions that the breakthrough was a “penicillin moment” for cancer researchers.
However, he said: “We have got to balance the hype and the hope. Cancer is complicated.”
- California scientists hail 'penicillin moment' in cancer treatment - Sep 15, 2010
- Pill to fight deadly skin cancer in sight - Jan 20, 2011
- How melanoma tumours evade drug treatment - Nov 25, 2010
- Scientists complete whole-exome sequencing of skin cancer - Apr 16, 2011
- New hope in the fight against melanoma - Dec 14, 2010
- It takes just 15 ciggies to raise lung cancer risk - Dec 17, 2009
- New pills shrink cancer tumours by half - Jul 24, 2010
- Zebrafish offers skin cancer clues - Apr 06, 2011
- Gene mutation behind onset of acute myeloid leukaemia identified - Mar 28, 2011
- Arthritis drug could help treat skin cancer - Mar 24, 2011
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
- New skin cancer pills 'can shrink tumours by up to 50pc' - Jul 24, 2010
- Distinguishing 'driver' from 'passenger' mutations in cancer genome - Feb 18, 2010
- 'Cell explosions' can trigger instant cancers - Jan 07, 2011
- Skin cancer pill showing 'remarkable' results, say researchers - Aug 26, 2010
Tags: bethesda maryland, cancer field, cancer treatment, daily telegraph, end game, gene mutation, genetic mutations, human genome research, human genome research institute, malignant melanoma patients, mark stratton, national human genome research, national human genome research institute, professor mark, research scientists, sir mark, speedy development, wellcome trust sanger, wellcome trust sanger institute, yardena